If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Half year results saw double digit growth with respect to revenue and profit. This looks set to continue going into the full year results. I predict the share price will creep up steadily. Broker views look optimistic but nevertheless expect the SP to rise this year.
Philip Cartmell, Chief Executive Officer, bought 158,800 shares in the company on the 16th September 2014 at a price of 6.25p. The Director now holds 1,896,720 shares
Investors are losing the faith.
I am content at the moment. Performance has improved since last years RNS at the same time in that operating loss is lower than it was last year. So things are improving. There is a steady order book in place. I'm just hoping that more orders can be added and we've seen evidence of a couple in recent months which won't obviously be a part of the RNS just gone. So there is reason to be optimistic.
CRA is not an investment where you'd put a lot in the pot. It's more of a prospective investment. Share price is low at the minute but I can't see it going much lower bar a catastrophe. So I think its a good time to get in. But I'm going to hold onto my quite substantial investment which I bought at 6.50.
I understand that Tuzistra was submitted for FDA approval on 30 June 2014. The FDA should then conduct a substantive review within 60 days. So does anyone know when VER is expecting a decision to be made? I’m guessing this should be at the end of August. However, it is rare that approval is granted first time and I fully expect VER to have to submit further information which will drag the approval into 2015.
If VER does get FDA approval expect big hikes in the SP.
Profit is profit.
But if you have some spare funds a re-investment in VER (at the current price) wouldn't be a bad bet. Can see this one increasing by 33%+.